| Sector |
Chemicals
|
Compare with Sector peers |
| Industry |
Chemicals
|
Compare with Industry peers |
| Website | http://www.arveelabs.com | |
| Market Cap | 256.60 Cr. | |
| Enterprise Value(EV) | 250.15 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.86 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 271.54 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 47.40 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 26.31 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 8.85 | Calculated using Price: 232.85 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.10 Cr. | 11,020,000 Shares |
| FaceValue | 10 | |
| About Arvee Laboratories (India) Ltd. | ||
| The company is mainly engaged in manufacturing of Polymer Modifiers, Contrast Media Intermediates and Drug Intermediates. The company caters to the demand of both domestic as well as international markets. Arvee Labs bought land, building and machineries from Skylink Chemicals who was engaged in manufacturing of specialty chemicals. Currently, it is negotiating with IDBI Bank to take over the business of Skylead Chemicals. | ||
| 1 Day |
|
+3.79% |
| 1 Week |
|
-1.90% |
| 1 Month |
|
+64.04% |
| 3 Month |
|
+41.12% |
| 6 Month |
|
+101.08% |
| 1 Year |
|
+120.40% |
| 2 Year |
|
+107.07% |
| 5 Year |
|
+639.21% |
| 10 Year |
|
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -73.58 | 9.24 | 45.41 | 12.01 | 14.97 | 13.17 | 13.38 | 11.36 | 15.84 | |
| Return on Capital Employed (%) | 7.51 | 14.39 | 15.19 | 17.69 | 14.1 | 15.79 | 15.99 | 13.33 | 23.35 | |
| Return on Assets (%) | -7.58 | 0.61 | 4.38 | 2.73 | 5.57 | 6.5 | 7.17 | 6.46 | 10.65 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 1 | 3 | 4 | 14 | 16 | 19 | 21 | 24 | 28 | 29 | |
| Non Curr. Liab. | 16 | 18 | 17 | 9 | 4 | 2 | 1 | 1 | 2 | 2 | |
| Curr. Liab. | 9 | 14 | 15 | 21 | 17 | 12 | 18 | 14 | 9 | 5 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 26 | 35 | 36 | 44 | 37 | 34 | 41 | 39 | 39 | 35 | |
| Non Curr. Assets | 14 | 18 | 17 | 17 | 16 | 16 | 15 | 15 | 17 | 15 | |
| Curr. Assets | 12 | 18 | 19 | 27 | 21 | 18 | 26 | 24 | 22 | 20 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | ||||||
| Total Assets | 26 | 35 | 36 | 44 | 37 | 34 | 41 | 39 | 39 | 35 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 13 | 27 | 34 | 48 | 55 | 45 | 47 | 40 | 61 | 37 | |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | |
| Total Income | 13 | 27 | 35 | 48 | 55 | 46 | 48 | 41 | 63 | 37 | |
| Total Expenditure | -11 | -22 | -29 | -41 | -49 | -39 | -41 | -35 | -54 | -33 | |
| PBIDT | 2 | 5 | 6 | 7 | 7 | 6 | 7 | 6 | 9 | 4 | |
| Interest | -2 | -3 | -3 | -3 | -2 | -1 | -1 | 0 | 0 | 0 | |
| Depreciation | -1 | -1 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | |
| Taxation | -1 | 0 | 1 | -1 | 0 | -1 | -1 | -1 | -2 | -1 | |
| Exceptional Items | |||||||||||
| PAT | -2 | 0 | 2 | 1 | 2 | 2 | 3 | 3 | 4 | 1 | |
| Adjusted EPS | -3 | 0 | 2 | 1 | 2 | 2 | 2 | 2 | 4 | 1 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 9 | 6 | 4 | 6 | 9 | 10 | 2 | 4 | 3 | |
| Cash Fr. Inv. | -6 | -6 | -5 | -1 | -1 | -3 | -3 | -1 | 0 | -1 | |
| Cash Fr. Finan. | 7 | -2 | -1 | -3 | -4 | -5 | -10 | 5 | -6 | -2 | |
| Net Change | 0 | 1 | 0 | 0 | 1 | 2 | -3 | 6 | -2 | -1 | |
| Cash & Cash Eqvt | 0 | 1 | 1 | 1 | 2 | 4 | 1 | 7 | 5 | 1 |
|
Mon, 22 Apr 2024
Disclosure under SEBI Takeover Regulations Arvee Laboratories (India) Limitedￂﾠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaￂﾠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.ￂﾠ |
|
Mon, 08 Apr 2024
Price movement Significant movement in price has been observed in Arvee Laboratories (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. |
|
Mon, 08 Apr 2024
Price movement Significant movement in price has been observed in Arvee Laboratories (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Arvee Laboratories (India) Limited has submitted their response. |
| Mon, 29 Apr 2024 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Closing Above Previous High
|
Closing Above Previous High For 3 Days
|
